Etoposide

Catalog No.S1225 Synonyms: VP-16, VP-16213

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 280 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • ABT-199 synergizes strongly with lymphoma chemotherapy agents that affect MCL1 levels. Viability and CI vs Fa after 24-h exposure to etoposide alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM.

    Leukemia, 2015, 29: 1702–1712. Etoposide purchased from Selleck.

    Dox promotes formation of DNA DSBs in primary neurons. (A) Cortical neurons at 28–32 DIV were treated with a vehicle or with Dox (0.1 μ M) or with DNA damaging drug etoposide (5 μ M) overnight, fixed, and stained for a marker of DSBs phosphorylated histone H2A variant X, γ H2A.X (green), MAP2c (red), and with the nuclear Hoechst dye (blue), and imaged. The neuronal nucleus is enlarged on the Dox panel to illustrate the γ H2A.X puncta. Note the green nuclear staining in cells treated with Dox and etoposide. Also note the reduced dendritic arborization in neurons treated with Dox and etoposide. Scale bar is 20 μm.

    Sci Rep, 2016, 6:25705.. Etoposide purchased from Selleck.

  • Viability of U87 cells(C) assessed by the Alamar blue assay, 72 h after transfection with siRNA anti-survivin (siSURV) or with siMUT and/or cell incubation with the chemotherapeutical drugs etoposide (ETO) and Bliss interaction index (D) determined for the combined effects on cell viability of survivin silencing plus treatment with each drug. Cells were transfected, for 4 h, with (14Ser)2N5/siRNA/HL complexes and, after an additional period of 20 h, cells were incubated with 1.5 μM ETO (C) for 48 h. Results, representative of at least three independent experiments, are expressed as a percentage of the nontreated control cells. Combined treatment (dotted bar) was compared with the single drug treatment (gray bar) (**p < 0.01, ***p < 0.001) and the Bliss interaction index of each combined treatment was compared with the theoretical value expected for an additive effect (1.0) (#p < 0.05, ns, non-significant).

    Eur J Pharm Biopharm, 2016, 104:7-19.. Etoposide purchased from Selleck.

    Cellular biomarker responses in HT29 cells exposed to various cytotoxic chemotherapeutic agents in combination with the Chk1 inhibitor V158411. HT29 cells were exposed to the combination GI80 of gemcitabine (0.2 uM), camptothecin (0.44 uM), cisplatin (68 uM), oxaliplatin (131 uM), doxorubicin (1.2 uM) or etoposide (59 uM) for 18 hours followed by DMSO (-) or 400 nM V158411 (+) for a further 24 hours. Protein expression was characterized by immunoblotting.

    BMC Cancer 2014 14, 483. Etoposide purchased from Selleck.

  • (c) and (d) Effects of fractions C4 and C5 on topoisomerase II activity. Topoisomerase II activity was measured by plasmid DNA cleavage assay. DNA bands were visualized using UV light and the intensity of linear DNA band in each lane was measured using imageJ software. Lane 1: plasmid PBR322DNA. Lane 2: control, topoisomerase II + plasmid PBR322DNA. Lanes 3, 4, and 5: 40, 20, and 10 μg/mL fraction C4 + plasmid PBR322DNA, respectively. Lanes 6, 7, and 8: 40, 20, and 10 μg/mL fraction C5 + plasmid PBR322DNA, respectively. Lane 9: 100 μM etoposide + plasmid PBR322DNA. The data in different groups were expressed as the mean ± SD from 3 experiments. Statistical difference between groups was assessed by t-test using SPSS 20.0. ∗∗P < 0.01 versus the control group.

    Evid Based Complement Alternat Med, 2017, 2017:1456786. Etoposide purchased from Selleck.

    Effects of etoposide on the radiosensitivities of cholangiocarcinoma cell lines. The cell survival curves of (A) KKU-M055 and (B) KKU-M214 cells were obtained from clonogenic survival assays. The cells were treated with X-ray irradiation or etoposide (0.025 or 0.05 µg/ml) alone or pretreated with etoposide for 24 h prior to X-ray irradiation. Survival fractions were determined at day 10 following X-ray irradiation. The dose-response curves depict the mean ± standard deviation of survival fractions of three independent experiments. IR, irradiation.

    Oncol Lett, 2018, 15(3):3895-3903. Etoposide purchased from Selleck.

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
Targets
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly MkfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHHbJhkUUN3ME2wMlEz6oDLwsJihKkxNjBzIN88US=> NGXVXpMzPTl4MEK4Ni=>
KellyCis83 MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXwU2NKSzVyPUCuNVbjiIoEsfMAjVAvODJizszN MV[yOVk3ODJ6Mh?=
SK-N-AS NFLodZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnrNpNKSzVyPUCuNlTjiIoEsfMAjVAvODNizszN NWKxboMyOjV7NkCyPFI>
SK-N-ASCis24 M1TOdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPrSXVsUUN3ME2wMlU46oDLwsJihKkxNjFzIN88US=> M4DnSlI2QTZyMkiy
U87 NGjEWJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnlfnpqOC13MDFOwG0> NY\u[JdFPDhiaB?= NHPFNYxl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImge4hq[2hiY3HuJIJmKGWwaHHuZ4VlKGK7IIPpcIljcW6rbh?= NH\ucIEzPTd3MEK3Ny=>
HCT116 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7jepcxNjVvMj61JO69VQ>? NVLnZYlJPDkEoHlCpC=> MmTRTWM2OD1zLkezxsDDucLiMD6yNeKh|ryP NUXRdHJWOjV5NE[3OlM>
HT-29 M1fHd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHJeFk1OC53LUKuOUDPxE1? MnvFOFjDqGkEoB?= M4P5OGlEPTB;Nz6yxsDDucLiMT6wOOKh|ryP M1r0eFI2PzR4N{[z
Caco2 NWn1fWhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlmyNE42NTJwNTFOwG0> MmWyOFjDqGkEoB?= NH3qWYlKSzVyPUeuNlbDqMLzwrCxMlY5yqEQvF2= NWjQOGlUOjV5NE[3OlM>
COLO 205 NG\ZUWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3v1flAvPS1{LkWg{txO M4HqeFQ5yqCqwrC= NFu0bXRKSzVyPUGuOlHDqMLzwrCwMlAzyqEQvF2= M3izflI2PzR4N{[z
SW480 Ml7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX2wMlUuOi53IN88US=> NVLhPJBoPDkEoHlCpC=> MlLlTWM2OD12LkmyxsDDucLiMD6zN:Kh|ryP MWiyOVc1Pjd4Mx?=
HEK293T M1zzPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHHTZYyNTVizszN M4LrNlQ5yqCqwrC= NH3MO3pKSzVyPUKuOFLDqMLzwrCwMlA2yqEQvF2= NYn4V|d3OjV5NE[3OlM>
Hep3B  M{HTWWZ2dmO2aX;uJGF{e2G7 Ml;ONVAh|ryP NXn5PY9wPDkEoHlCpC=> MoTBdoVlfWOnczD0bIUh\W6qYX7jbY5oKGWoZnXjeEBw\iCETWCtOi=> MknENlU3OzN3NkS=
Hep3B  NYLQXIROTnWwY4Tpc44hSXO|YYm= Ml2zNE4yNTFyIN88US=> NFP3e5YzPCCq NULDOJZ2e3WycILld5NmeyC2aHWg[ZhxemW|c3nvckBw\iCqZYDjbYRqdiCvUl7B NWrjSpBGOjV4M{O1OlQ>
HEK293 Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPKTWM2OD15LkG0xsDDucLiMD6zOuKh|ryP M{CyblI2PjB|MUKy
DU145 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzyd|JKSzVyPUKuNljDqMLzwrCwMlA1yqEQvF2= NF7oPXMzPTZyM{GyNi=>
HCT15 NH3JbVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwOEJCpOKyyqByLkCxxsDPxE1? NXu3WItmOjV4MEOxNlI>
T47D MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjQTWM2OD1|LkG4xsDDucLiMD6xNeKh|ryP MY[yOVYxOzF{Mh?=
SMMC-7721 MU\GeY5kfGmxbjDBd5NigQ>? M3njU|QxKM7:TR?= M1j3dVQ5KGh? M4f3b2ROW09? M3PNS4lv\HWlZYOg{tNJOkG[IH\vZ4kh\m:{bXH0bY9v NHLWUmwzPTV2NEO2NS=>
MDA-MB-231 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\VcVczyqCq MnvkTWM2OD1{MT6yxsDDucLiND6yxsDPxE1? MXWyOVQ5PjJzOR?=
MCF-7 NV\4RWh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LNcFczyqCq MoG1TWM2OD1zMD65xsDDucLiMj6xxsDPxE1? M4jBbVI2PDh4MkG5
Jurkat NF3aTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjsZlY4OsLiaB?= NF;xOZZKSzVyPUGuNuKhyrIEoEGuOeKh|ryP NVzYbGRlOjV2OE[yNVk>
HeLa MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXW3NuKhcA>? NGezXFVKSzVyPUOuPeKhyrIEoEKuN:Kh|ryP MX[yOVQ5PjJzOR?=
MCF7  NGK4cWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF:wb2E2NTFyMDFOwG0> NHTh[Xk4KGR? M3fRXYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M2C1eVI2PDd{NkG5
K562 M{X1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHW3SYQ4OsLiaB?= NXLrNJZxUUN3ME2wMlI6yqEQvF2= MkXqNlUzQDJ4NUO=
K/VP.5 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXO3NuKhcA>? M3XM[2lEPTB;ND65xsDPxE1? M2jK[|I2Ojh{NkWz
SH-EP  MUHGeY5kfGmxbjDBd5NigQ>? NXHWeoE4OjEEoN88[{9udA>? MWiyOOKhcA>? MkXhbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJIVv\G:pZX7veZMhTEWSUB?= NFTueHMzPTJ4MUm4NS=>
SCC25 M3XNdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXf5ZXVOOjUEoHi= NV7IeZhrUUN3ME20N{4{yqEEsdMgNU4yOsLizszN Ml;0NlUzOjB5Mkm=
CAL27 NV3mfZdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVqyOOKhcA>? MnXxTWM2OD13Mj6xxsDDucLiMT6wPeKh|ryP NYTabVY6OjV{MkC3Nlk>
FaDu NHH0WItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFraOVUzPMLiaB?= MWjJR|UxRTJ3Lki5xsDDucLiMT6xN:Kh|ryP NU\UVGs3OjV{MkC3Nlk>
SCC25 NG\Ve3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnmXmQ3PDkEoHi= NIfpPW1KSzVyPUKwMlg3yqEEsdMgNU4xP8LizszN NV3VWYdDOjV{MkC3Nlk>
CAL27 MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHO3XVA1QMLiaB?= NWXiVJRCUUN3ME2xPE4zPMLiwsJCpFEvOTYEoN88US=> NGHxWmIzPTJ{MEeyPS=>
FaDu NF63S2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3aNFNIPDkEoHi= M{K2XWlEPTB;Nj60N:KhyrIEoEGuNVPDqM7:TR?= M3zHSlI2OjJyN{K5
SCC25 MoHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HlUFczyqCq NXvwOIlzUUN3ME24MlQyyqEEsdMgNU4yOcLizszN M4DON|I2OjJyN{K5
CAL27 NYTnWW9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrvd5k4OsLiaB?= NXTyRm9MUUN3ME20MlI4yqEEsdMgNU4yPMLizszN NFjWSWgzPTJ{MEeyPS=>
FaDu MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvtNlZLPzMEoHi= M4\RUWlEPTB;NT6wNuKhyrIEoEGuNVXDqM7:TR?= MUeyOVIzODd{OR?=
MCF-7 M{\pXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHHeGM1QMLiaNMg NYrZTFNRTE2VTx?= NIDCd3FKSzVyPUeuNuKhyrIEoECuPOKh|ryP NVvtXVQyOjV{MU[zO|g>
T-47D MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYW0POKhcMLi NVnqSlN4TE2VTx?= NHS5cWpKSzVyPUeuO:KhyrIEoECuO:Kh|ryP MX6yOVIyPjN5OB?=
MDA-MB-231 NU[2UXh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nLeFQ5yqCqwrC= MnzISG1UVw>? NIjQcIZKSzVyPUGyMljDqMLzwrCxMlDDqM7:TR?= NU\ESFlROjV{MU[zO|g>
DU145 MUjBdI9xfG:|aYOgRZN{[Xl? Mnu5NVAuOTByIN88US=> NF;WdGI5KGh? MYnEUXNQ MnPjbY5lfWOnczDj[YxtKGSnYYToJJNq\26rZnnjZY51dHliaX6gZUB3\XK7IHzve{Bkd26lZX70doF1cW:w MXqyOVE1QTZ6MR?=
DU145 stem-like MmLVRZBweHSxc3nzJGF{e2G7 Ml7DNVAuOTByIN88US=> M2L5W|ghcA>? NH30OG5FVVOR MVXpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NUP6S|hqOjVzNEm2PFE>
DU145 MlS0SpVv[3Srb36gRZN{[Xl? M4nYTVExNTFyMDFOwG0> MWGyJIg> MmrhSG1UVw>? NVO3O3JmcW6lcnXhd4V{KHSqZTDwR2hMOSCneIDy[ZN{cW:wIHHu[EBl\WO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NIDnSpQzPTF2OU[4NS=>
DU145 stem-like MlLsSpVv[3Srb36gRZN{[Xl? NFvLflAyOC1zMECg{txO NX:4N5pNOiCq NV7MSpJvTE2VTx?= NF3UT5JqdmO{ZXHz[ZMhfGinIIDDTGsyKGW6cILld5Nqd25iYX7kJIRm[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M2S0S|I2OTR7Nkix
UW228-3 MoTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjSOVBVOC5yMT2zNFAh|ryP NXzr[ZRXPDhiaB?= MmPkSG1UVw>? MlXjTWM2OD1yLkm5xsDPxE1? MkfLNlUyOTlzOEW=
NSCs NYrKUHI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX:wMlAyNTNyMDFOwG0> NGrFb|k1QCCq NV;0SVRwTE2VTx?= NVnNZ3NbUUN3ME2wMlMuO8LizszN MYiyOVEyQTF6NR?=
MKL-1  MmPhSpVv[3Srb36gRZN{[Xl? NY[4fI9MOTBvMUCwNEBvVQ>? M4HYNlQh\A>? M4\qeolv\HWlZYOgeIhmKGmwZIXjeIlwdiCxZjDNTGMuUSCneIDy[ZN{cW:w M1LQTlI2OTF4N{W0
MCF7 EV MYPGeY5kfGmxbjDBd5NigQ>? NH;WWHkyOC1zMECg{txO NHjTc2Yz6oDLaB?= M2POZ4lv\HWlZYOgdJJw\HWldHnvckBw\sLizsPINmFZ Mom5NlUxQDh{MEO=
MCF 7BMI1 M3n0N2Z2dmO2aX;uJGF{e2G7 NYfW[3dYOTBvMUCwJO69VQ>? NHG5VlAz6oDLaB?= NXXwNlA1cW6mdXPld{Bxem:mdXP0bY9vKG:owrFOt2gzSVh? NGX3bWEzPTB6OEKwNy=>
MCF7 EV MUHGeY5kfGmxbjDBd5NigQ>? NVraWpBiOTBvMUCwJO69VQ>? NVv4eVRLOuLCiXi= M373NmVVV1BiaX7keYNmeyCDVF2gZYN1cX[jdHnvci=> MojhNlUxQDh{MEO=
MCF7 BMI1 MnTuSpVv[3Srb36gRZN{[Xl? NXHWb5NtOTBvMUCwJO69VQ>? M4\XTVLjiImq M{ezUWVVV1BiaX7keYNmeyCDVF2gZYN1cX[jdHnvci=> NYT4dolwOjVyOEiyNFM>
HepG2 M2[2fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MormSG1UV8Li NWnzXWNLUUN3ME2zNE4yPsLiwsJCpFAvPTEEoN88US=> M2LiO|I2ODd6M{Gx
MOLT-3 M{DGdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPUSG1UV8Li MmjFTWM2OD1yLkC1NeKhyrIEoECuNFAzyqEQvF2= M1XsdVI2ODd6M{Gx
HT1080 MlTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1u1OVEuOTByIN88US=> M3;kcFQwOjRxNEigbC=> M4fwVWROW00EoB?= M1nQeolv\HWlZYOgZ4VtdCCmZXH0bEB{cWewaX\pZ4FvfGy7IHnuJIEhfmW{eTDsc5ch[2:wY3XueJJifGmxbh?= NWf1PHB2OjVyN{iwOlQ>
HT1080 NWG2VW5kTnWwY4Tpc44hSXO|YYm= NWC0XopyOC5yMECxMVExOCEQvF2= M4f4PVEuOjRiaB?= Ml3CSG1UV8Li MYXpcoR2[2W|IICtdFU{MHOnckG1LUBqdiCkb4ToJJRqdWVvIHHu[EBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? NI\HWHQzPTB5OEC2OC=>
HT1080 NIHtcIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInrSYcxNjByMEGtNVAxKM7:TR?= Ml\6NlQhcA>? M1\0NGROW00EoB?= MUjjZZV{\XNiYX6gbY5kemWjc3WgbY4hfGinIH71cYJmeiCxZjDj[YxteyCrbjDHNk9ONCC5aHns[UBl\WO{ZXHzbY5oKFNiYX7kJGcyKHCqYYPlJINmdGy| NUmyZ4piOjVyN{iwOlQ>
HD-MY-Z NGX2TXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPwNlQwPDhxN{KgbC=> MUHJR|Ux97zgMUCwJO69VQ>? NVrWfYZpOjVyNEiyN|Y>
DOHH-2 MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVT0NW1HOjRiaB?= NUj0eVB1UUN3MP-8olExOCEQvF2= NYK1V3pmOjVyNEiyN|Y>
DOHH-2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV20PEBp M{DnTWlEPTB;MUmuPeKh|ryP M3zFRlI2ODR6MkO2
DOHH-2 NVXOfpVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoqzO|IhcA>? Mkm4TWM2OD13wrFOwG0> M4XjW|I2ODR6MkO2
REH M{G3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEW3PHczPCCq NYrVb4tbUUN3ME2wMlAzP8LizszN MUSyOVA1QDJ|Nh?=
REH NFfk[XhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPhOFghcA>? M4n0fGlEPTB;MD6wNVTDqM7:TR?= MYmyOVA1QDJ|Nh?=
REH NWrmZW5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{GwXlczKGh? M4DOSGlEPTB;MD6wNVXDqM7:TR?= M4L0WlI2ODR6MkO2
HH MkntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\aSJgzPCCq M{\memlEPTB;MUC0MlfDqM7:TR?= M2nUTlI2ODR6MkO2
HH MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVm0PEBp M4\LdmlEPTB;NEiuOuKh|ryP MnPqNlUxPDh{M{[=
HH NHT5[ldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jv[lczKGh? M4PBdmlEPTB;MUSuO:Kh|ryP Mn\BNlUxPDh{M{[=
HuT-78 Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\NNlQhcA>? NHPUfm1KSzVyPUmuN:Kh|ryP Ml;rNlUxPDh{M{[=
HuT-78 MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDLOFghcA>? NHfFellKSzVyPUSuN:Kh|ryP MXOyOVA1QDJ|Nh?=
HuT-78 NV\aSHBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\KO|IhcA>? M2PMOWlEPTB;ND6yxsDPxE1? NXW2S|I4OjVyNEiyN|Y>
OPM-2 NF3od3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrUcWJYOjRiaB?= MWLJR|UxRTJ2LkJCpO69VQ>? MkXVNlUxPDh{M{[=
OPM-2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3f3NlQ5KGh? MofiTWM2OD12wrFOwG0> MXKyOVA1QDJ|Nh?=
OPM-2 NX3M[|h5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXK3NkBp NX75ZXhsUUN3ME2xMlPDqM7:TR?= M2eyZ|I2ODR6MkO2
RPMI-8226 NUXoV2RKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfkdHAzPCCq NV;QU|Z6UUN3ME2xNFYvPsLizszN MXWyOVA1QDJ|Nh?=
RPMI-8226 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnTbo81QCCq MVnJR|UxRTlzLkJCpO69VQ>? M4CyWVI2ODR6MkO2
RPMI-8226 M2nyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvCdGM4OiCq NVPy[pZWUUN3ME2xOE46yqEQvF2= Mn[4NlUxPDh{M{[=
U-266 M{L1UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfHZ3AzPCCq NW\6XZZ3UUN3ME24Ok4zyqEQvF2= M4Dqc|I2ODR6MkO2
U-266 NUDqVnlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rBN|Q5KGh? M1nkV2lEPTB;NkiuOOKh|ryP M{jYcFI2ODR6MkO2
U-266 M2P3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYS3NkBp MXvJR|UxRTJ5LkVCpO69VQ>? NFnBc48zPTB2OEKzOi=>
Kelly M{L3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\ReZExNTFyIN88US=> MWq3NuKhcA>? MX;JR|UxRTFwNUG4xsDPxE1? Ml:zNlUxODh7MEC=
SH-SY5Y  NW\yUXpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnvOWIxNTFyIN88US=> Ml:wO|LDqGh? NFrSOlVKSzVyPUCuO|U1yqEQvF5CpC=> Mne4NlUxODh7MEC=
SK-N-AS M{fTTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1WyWVAuOTBizszN Mlv1O|LDqGh? M4j5VmlEPTB;MT63NVLDqM7:TdMg MYCyOVAxQDlyMB?=
SK-N-DZ MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLnN44xNTFyIN88US=> MWi3NuKhcA>? NEfJ[FZKSzVyPUWuOFg2yqEQvF2= M4TtW|I2ODB6OUCw
HepG2 NX\MZ3hxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonBOFjDqGh? NULPcpY4TE2VT9Mg MlPYTWM2OD1zMz62OeKhyrIEoECuPVLDqM7:TR?= M3vYUVI1QTl4MUO2
A549 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHyXIFSPDkEoHi= Mk\uSG1UV8Li NEH0TpVKSzVyPUK0NU46yqEEsdMgN|EvOjQEoN88US=> NVfS[2pnOjR7OU[xN|Y>
MCF7 NVrIXHNPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrTZpM1QMLiaB?= NVzFSXVxTE2VT9Mg NVH5bWdKUUN3ME24NU4xQcLiwsJCpFE1NjJzwrFOwG0> NI\Ed4wzPDl7NkGzOi=>
HL-60  Mnu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{T2dFczyqCq MVLJR|UxRTBwMUNihKXPxE1? MUOyOFk6OzBzNB?=
HL-60[R] NF\1fm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGK2S|Y4OsLiaB?= MnPmTWM2OD1|LkGy5qCG|ryP MkTCNlQ6QTNyMUS=
MIAPACA NI\qNW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XTTGdKPTB;MT6zJOKyKDBwMEOg{txO MUmyOFk2Ozh{MR?=
MCF-7 M3\4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfHTVUxRTBwMkWgxtEhOC5zIN88US=> MUiyOFk2Ozh{MR?=
HeLa MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;aS2k2OD1yLk[0JOKyKDBwNDFOwG0> NV\VSoZsOjR7NUO4NlE>
MO59K  MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHCO{Bl NFHzV4JKSzVyPUCuNVfjiIYQvF2= NFjadWYzPDl3M{W2NS=>
MO59J M3v4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrMO2tjPyCm NITze3ZKSzVyPUCuNgKBjc7:TR?= NWXBOVhbOjR7NUO1OlE>
ME 180 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXu0POKhcMLi MWXJR|UxRThwOdMgxtHDqDBwM,MAie69VQ>? MkjDNlQ6PTNyMke=
MCF-7 M17P[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H2N|Q5yqCqwrC= M13VNGlEPTB;MkOuPUDDuSByLkRihKXPxE1? MmTINlQ6PTNyMke=
HeLa NWexNJl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4KyNlQ5yqCqwrC= M3LMcWlEPTB;ND63NUDDuSBzLkVihKXPxE1? MV2yOFk2OzB{Nx?=
MDA-MB-453 NET3PVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:1bZU1QMLiaNMg NXnrWGxPUUN3ME2xNk42KMLzIECuPFXjiIYQvF2= MkDINlQ6PTNyMke=
MDA-MB-231 NEXoVlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVe0POKhcMLi NHS4T2RKSzVyPUK0MlIzKMLzIEKuPVTjiIYQvF2= Ml3ONlQ6PTNyMke=
PC-3 MlqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7oOFjDqGkEoB?= MUDJR|UxRTF2LkSgxtEhOy5{M,MAie69VQ>? NIjuZW0zPDl3M{CyOy=>
HT-29 M4S5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2WzUFQ5yqCqwrC= NYHnR5VuUUN3ME2yNU41PSEEsTCzMlg46oDHzszN M{HkdlI1QTV|MEK3
BGC-823 NXHnN2w1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTZT4xKPDkEoHlCpC=> NGLUTpZKSzVyPUSzMlc1KMLzIEWuNVPjiIYQvF2= NVjzR4I{OjR5OUO4O|c>
HeLa MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITKc5g1QMLiaNMg NFLvUGdKSzVyPUKwPU46OCEEsTCxN{41OiEkgJZOwG0> NUC0Z2pMOjR5OUO4O|c>
A549 M334[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX[0POKhcMLi MnPMTWM2OD1zM{muOVQhyrFiNz6wOgKBjc7:TR?= M3TrN|I1Pzl|OEe3
HK-2 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zydFQ5yqCqwrC= NILifG5KSzVyPUmuNVchyrFiMT61PQKBjc7:TR?= NIjQOmYzPDd7M{i3Oy=>

... Click to View More Cell Line Experimental Data

In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

Protocol

Kinase Assay:[5]
+ Expand

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research:[5]
+ Expand
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Formulation: Saline
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+H2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56
Formula

C29H32O13

CAS No. 33419-42-0
Storage powder
in solvent
Synonyms VP-16, VP-16213

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03583424 Recruiting Hematopoietic Cell Transplantation Recipient|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Non-Hodgkin Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Marginal Zone Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Transformed Indolent Non-Hodgkin Lymphoma Ohio State University Comprehensive Cancer Center|National Cancer Institute (NCI) July 9 2018 Phase 1|Phase 2
NCT03136146 Recruiting Hematopoietic/Lymphoid Cancer|Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma|Burkitt Leukemia/Lymphoma M.D. Anderson Cancer Center August 9 2017 Phase 2
NCT01458366 Active not recruiting Non-Hodgkin''s Lymphoma Sidney Kimmel Cancer Center at Thomas Jefferson University|GlaxoSmithKline|Novartis|Thomas Jefferson University November 9 2011 Phase 1|Phase 2
NCT03016871 Recruiting CD (Cluster of Differentiation) 30-Positive Neoplastic Cells Present|Recurrent Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|TNFRSF8 Positive City of Hope Medical Center|National Cancer Institute (NCI) May 8 2017 Phase 2
NCT03067181 Recruiting Adult Germ Cell Tumor|Childhood Extracranial Germ Cell Tumor|Childhood Germ Cell Tumor|Extragonadal Embryonal Carcinoma|Grade 2 Immature Ovarian Teratoma|Grade 3 Immature Ovarian Teratoma|Malignant Germ Cell Tumor|Stage I Ovarian Choriocarcinoma|Stage I Ovarian Embryonal Carcinoma|Stage I Ovarian Teratoma|Stage I Ovarian Yolk Sac Tumor|Stage I Testicular Choriocarcinoma AJCC v6 and v7|Stage I Testicular Embryonal Carcinoma AJCC v6 and v7|Stage I Testicular Yolk Sac Tumor AJCC v6 and v7|Stage II Ovarian Choriocarcinoma|Stage II Ovarian Embryonal Carcinoma|Stage II Ovarian Yolk Sac Tumor|Stage II Testicular Choriocarcinoma AJCC v6 and v7|Stage II Testicular Embryonal Carcinoma AJCC v6 and v7|Stage II Testicular Yolk Sac Tumor AJCC v6 and v7|Stage III Ovarian Choriocarcinoma|Stage III Ovarian Embryonal Carcinoma|Stage III Ovarian Yolk Sac Tumor|Stage III Testicular Choriocarcinoma AJCC v6 and v7|Stage III Testicular Embryonal Carcinoma AJCC v6 and v7|Stage III Testicular Yolk Sac Tumor AJCC v6 and v7|Stage IV Ovarian Choriocarcinoma|Stage IV Ovarian Embryonal Carcinoma|Stage IV Ovarian Yolk Sac Tumor|Testicular Mixed Choriocarcinoma and Embryonal Carcinoma|Testicular Mixed Choriocarcinoma and Teratoma|Testicular Mixed Choriocarcinoma and Yolk Sac Tumor Children''s Oncology Group|National Cancer Institute (NCI) May 8 2017 Phase 3
NCT02070458 Active not recruiting Recurrent Adult Acute Myeloid Leukemia|Refractory Acute Myeloid Leukemia Case Comprehensive Cancer Center|National Cancer Institute (NCI) October 8 2014 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • Answer:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID